Jefferies analyst Andrew Tsai said Moderna may have more than seven products on the market by 2027-28, with 2026 revenue potentially growing up to 10% from 2025's $1.9 billion, and breakeven possible by 2028.
Jin1008/20, 04:31 PM
Related assets
Coming up for MRNA
Explore next
Latest MRNA news
Jin1010/23, 05:33 AM
Jin1010/23, 03:02 AM
Jin1010/23, 12:41 AM